{
    "Trade/Device Name(s)": [
        "HYDRASHIFT 2/4 daratumumab"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K190851",
    "Predicate Device Reference 510(k) Number(s)": [
        "K172195"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFF"
    ],
    "Summary Letter Date": "May 2, 2019",
    "Summary Letter Received Date": "April 2, 2019",
    "Submission Date": "March 5, 2019",
    "Regulation Number(s)": [
        "21CFR866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Immunoglobulin G",
        "Immunoglobulin A",
        "Immunoglobulin M",
        "Kappa light chain",
        "Lambda light chain",
        "Daratumumab"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "HYDRASYS 2"
    ],
    "Method(s)/Technology(ies)": [
        "Agarose gel electrophoresis",
        "Immunofixation electrophoresis"
    ],
    "Methodologies": [
        "Immunofixation"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for HYDRASHIFT 2/4 daratumumab kit for qualitative detection of monoclonal proteins in human serum using immunofixation electrophoresis",
    "Indications for Use Summary": "Qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis in conjunction with HYDRAGEL IF kits and HYDRASYS 2 apparatus, enabling visual evaluation of monoclonal proteins in patients who have received daratumumab therapy",
    "fda_folder": "Immunology"
}